Priority 4 - Innovation
Facilitate the rapid assessment of new technologies for potential national adoption. Where these are approved, lead the accelerated implementation of these technologies on a once for Scotland basis
Responsible Team: Innovation Team
Ongoing assessment and support to existing innovations being progressed through the pathway
A total of 4 projects are currently undergoing assessment through the ANIA pathway. This includes assessing how new Artificial Intelligence and Genomics technologies could be adopted on a national basis.
These innovations have the potential to improve lung cancer outcomes reduce the number of strokes and prevent infant deafness across Scotland. Final Value Cases for three of these projects are due to be presented to the Innovation Design Authority (IDA) by the end of December 2024.
The IDA is the Scottish Government board that makes decisions related to ANIA innovations.
Accelerated implementation of innovations that have been approved by the Innovation Design Authority (IDA) for national adoption
A total of 4 projects (Digital Dermatology, Diabetes Closed Loop System (CLS), CytoSCOT and Digital Diabetes remission) have been approved by the Innovation Design Authority for national adoption.
National implementation teams for Digital Dermatology and CLS have been formed. These teams will be responsible for supporting Boards with the national adoption of these solutions.
Clinical leads to support the roll out of Digital Dermatology are now in place. The supplier has carried out demonstrations for Health Boards, and data mapping for the National Digital Platform is ongoing. A communications plan and training package are in the process of being developed.
The initial three cohorts of CLS participants have been on-boarded successfully, and the initial feedback has been positive. A national CLS event was held, which has increased awareness of the programme. The National Clinical Advisory Group are currently reviewing referrals and clinical processes prior to further roll-out
The CytoSCOT Value Case was also approved in 23/24 via the ANIA pathway. This is now been implemented across Scotland as a business as usual clinical service.
Digital Diabetes Remission was recently approved by the IDA. Over the next year, national implementation work will continue.
Ongoing development of ANIA governance arrangements and ANIA pathway
There is a process of continual improvement to refine and revise the governance arrangements as required. Over the last year, a revised Accelerated National Innovation Adoption (ANIA) Operating Model was agreed, which sets out how to make the case for investment in high-impact technologies.
Develop strategic partnerships including engagement with Boards
Over the year CfSD has co-ordinated an ANIA delivery partnership on behalf of the Scottish Government. This is made up of a number of National Boards including Healthcare Improvement Scotland, Public Health Scotland, National Services Scotland and NHS Education for Scotland.
Explore research and publish evidence based learning from nationally adopted Innovations
The team have worked with with ANIA partners to develop a process to support the active dissemination of knowledge through the publication of academic papers. This will enable the team to share best practice and promote the work of CfSD.